Astrazeneca’s Trixeo Aerosphere approved as first inhaled respiratory medicine using next-generation propellant with near-zero global warming potential

AstraZeneca’s Trixeo Aerosphere has officially been approved for use in the UK with an innovative, next-generation propellant with near-zero Global Warming Potential (GWP).^1,2 This is the first medicine delivered by a pressurised metered-dose inhaler (pMDI) approved with the propellant that has 99.9% lower GWP than propellants used in currently available pMDIs.  Trixeo with the next-generation propellant will have a low carbon footprint, comparable to inhaled medicines that do not require a propellant. Trixeo, a fixed-dose triple-combination therapy, is marketed as Breztri Aerosphere in the US, China and Japan.

Omar Usmani, Professor of Respiratory Medicine at Imperial College London, said: “Pressurised metered-dose inhaled medicines are essential for millions of people living with respiratory diseases in the UK. The transition of Trixeo to the propellant with near-zero Global Warming Potential means that healthcare professionals can focus on optimising outcomes for their COPD patients based on clinical need, while also supporting climate goals. Clinicians and their patients shouldn’t feel that they have to choose between the most appropriate treatment and the planet.”

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca, said: “The UK approval of Trixeo Aerosphere with the next-generation propellant is an industry first and a major milestone in AstraZeneca’s commitment to transition our pMDI portfolio to the propellant with near-zero Global Warming Potential. Starting with Trixeo, we are addressing the needs of both patients and the environment in devastating diseases like COPD, which affects hundreds of millions of people and is a leading cause of death globally.”

Tom Keith-Roach, President, AstraZeneca UK, said: “The UK approval of Trixeo Aerosphere with the near-zero Global Warming Potential propellant marks a world ‘first’ and an important step in improving the environmental impact of our portfolio of inhaled respiratory medicines to support the NHS in achieving its net zero carbon goals. Trixeo with our next-generation propellant allows us to address the needs of both patients and the planet.”

Note that Trixeois is the first medicine in AstraZeneca’s portfolio of pMDIs to transition to the new propellant. AstraZeneca aims to transition its wider pMDI portfolio to the near-zero GWP propellant by 2030 as part of the Company’s Ambition Zero Carbon strategy. In the UK, they to initiate the transition of Trixeo to the next-generation propellant in the coming months.

---

---

Related Topics and Keywords

AstraZeneca, Trixeo, Trixeo Aerosphere